Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
 - EconoTimes)
NEW ORLEANS, Jan. 06, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until January 17, 2017 to file lead plaintiff applications in a securities class action lawsuit against Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), if they purchased the Company’s securities between the expanded period of February 10, 2014 and December 9, 2016, inclusive (the “Class Period”). The action is pending in United States District Court, District of Connecticut.
What You May Do
If you purchased securities of Alexion and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by January 17, 2017.
About the Lawsuit
Alexion and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) Alexion employed improper sales practices with respect to its product Soliris; (ii) that the Company’s revenues from Soliris sales were unlikely to be sustainable; and (iii) as a result of the foregoing, Alexion’s public statements were materially false and misleading at all relevant times.
Additionally, on December 12, 2016, Alexion announced the unscheduled departure of CEO David Hallal and CFO Vikas Sinha, who both resigned effective immediately.
On this news, the price of Alexion’s shares again plummeted.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
